GlassScriptPhysician profile
Kara Arnold
NPI 1790394443
$4,527.52
in general payments reported to CMS, 2019-2025
22 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $508 · 2023: $1,893 · 2024: $1,667 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,576 · Education: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,575.81 |
| Education | $443.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,076.22 | 2022-2025 | |
| Janssen Biotech, INC. | $606.88 | 2022-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $484.39 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $307.55 | 2022-2024 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $288.55 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $269.84 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $249.86 | 2022-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $200.27 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $184.09 | 2022-2024 | Dupixent, Libtayo |
| Pfizer INC. | $181.61 | 2023-2025 | |
| Ucb, INC. | $119.36 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $118.77 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $98.42 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.43 | 2023-2024 | Siliq, Targretin |
| Elekta, INC. | $51.58 | 2024 | Elekta Medical Linear Accelerator |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $49.18 | 2023 | Vtama |
| Leo Pharma INC. | $38.25 | 2022-2024 | Adbry |
| Krystal Biotech INC | $36.19 | 2024 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.95 | 2023-2024 | Spevigo |
| Organon LLC | $33.96 | 2024 | |
| Galderma Laboratories, L.P. | $21.91 | 2025 | Nemluvio |
| Mylan Institutional INC. | $18.26 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.